449-55-8

Usage

Uses

Used in Pharmaceutical Industry:
6,11-Dihydro-5H-dibenzo[b,e]azepine is used as a core structure for the development of psychoactive drugs, specifically for the synthesis of certain antidepressants and antipsychotics. Its unique molecular configuration allows for the creation of compounds that can effectively target and modulate neurotransmitter systems in the brain, providing therapeutic benefits for various mental health conditions.
Used in Research and Development:
6,11-Dihydro-5H-dibenzo[b,e]azepine serves as a valuable compound in the field of medicinal chemistry, where it is used as a starting material for the synthesis of novel psychoactive substances. Researchers can modify the core structure by attaching different chemical groups to explore new drug candidates with potential therapeutic applications, such as improved efficacy, reduced side effects, or targeted drug delivery.
Used in Drug Delivery Systems:
In the development of drug delivery systems, 6,11-dihydro-5H-dibenzo[b,e]azepine can be incorporated into various formulations, such as nanoparticles or liposomes, to enhance the bioavailability and therapeutic outcomes of the resulting psychoactive drugs. By optimizing the drug's release and distribution within the body, these systems can improve the overall effectiveness and safety of treatment for patients with mental health disorders.

InChI:InChI=1/C14H13N/c1-2-7-13-10-15-14-8-4-3-6-12(14)9-11(13)5-1/h1-8,15H,9-10H2

Upstream product

• 1211-06-9 5,11-dihydro-6H-dibenz[b,e]azepin-6-one 
• 1143-50-6 5,6-dihydro-6,11-dioxomorphanthridine 
• 256-86-0 Morphanthridine 
• 1722-07-2 (2-(benzylamino)phenyl)methanol 
• 5344-90-1 2-Aminobenzyl alcohol 
• 85-52-9 2-Benzoylbenzoic acid 
• 147611-22-1 2-(benzylamino)benzaldehyde 
• 3311-41-9 5-benzyl-5,11-dihydro-6H-dibenzo[b,e]azepin-6-one 
• 1246775-61-0 2-[((4-methoxyphenyl)methyl)amino]benzaldehyde 
• 82085-86-7 2-phenyl-1,4-dihydro-2H-benz[d][1,3]oxazine 
• 1557-41-1 N-[2-(phenylmethyl)phenyl]formamide 
• 28059-64-5 2-benzylaniline 
• 100-52-7 benzaldehyde 

Downstream Products

• 73-07-4 N-<3-Dimethylamino-propyl>-homoacridan 
• 102166-72-3 N-(2-Diethylamino-ethyl)-homoacridan 
• 82342-52-7 N-benzoyl-5,6-dihydro-11H-dibenzazepine 
• 169878-67-5 N-[4-[(6,11-Dihydro-5H-dibenz[b,e]azepin-5-yl)-carbonyl]phenyl]-2-methylbenzamide 
• 3311-42-0 N-benzyl-5,6-dihydro-11H-dibenzazepine 
• 82342-54-9 5-Benzoyl-5,11-dihydro-dibenzo[b,e]azepin-6-one 
• 256-86-0 Morphanthridine 
• 41218-84-2 6-aminomethyl-6,11-dihydro-5H-dibenzo[b,e]azepine 
• 71936-92-0 1,2,3,4,10,14b-hexahydrodibenzo[c,f]-pyrazino[1,2-a]azepine 
• 24219-97-4 mianserin 
• 1334412-02-0 5-(4-nitrophenylthio)-6,11-dihydro-5H-dibenzo[b,e]azepine 

Relevant academic research and scientific papers

A Modular Approach to Dibenzo-fused ?-Lactams: Palladium-Catalyzed Bridging-C?H Activation

Tricyclic ring systems possessing a dibenzo structure joined to a seven-membered heterocyclic ring frequently show important biological activities. However, a modular approach to these molecules based on efficient intermolecular reaction of readily available chemicals is lacking. Herein, an unprecedented palladium-catalyzed formal [4+3] annulation for modular construction of these tricyclic systems is described. This reaction features easily accessible reactants (o-haloarylaldehydes and N-tosylhydrazones), broad substrate scope, and excellent functional group compatibility. The synthetic potential is demonstrated by the easy scale-up reactions, late-stage modification of complex molecules, and collective synthesis of bioactive molecules and approved drugs.

2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS

The invention relates to novel tetrahydro-lH-carbazole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to patients.

INDOL-1-YL-ACETIC ACID DERIVATIVES

The invention relates to indol-1-yl-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds.

Novel derivatives and analogues of galanthamin

New compounds of general formula I 1

Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: A novel series of 5-HT2A/2C receptor antagonists. Part 1

The synthesis of a series of novel 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives as well as their 5-HT2A/2C and H1 receptor binding affinities are described. The in vivo activity as potential anxiolytics of the synthesised compounds was measured in a mCPP challenge test. One of the compounds, 2a, proved to be a potent 5-HT2A/2C receptor antagonist showing as well oral activity and therefore could be considered as a potential anxiolytic/antidepressant agent.

Development of a safe and scalable amine-to-nitrone oxidation: A key step in the synthesis of R107500

The stepwise optimization towards a safe, reproducible, and high-yielding oxidation of azepine 2 into the prochiral nitrone 4 is described, with emphasis on the elimination of Davis reagent 3. m-Chloroperoxybenzoic acid (mCPBA) was found to be an elegant and scalable alternative oxidant regarding safety, yield, and easy workup procedures. Nitrone 4 was obtained in 95% yield and used without purification or isolation in the cycload-dition step to provide oxazolidone 6 in high yield. The process was scaled up successfully to an 800-L scale (60 mol of starting material).